References to Primary Literature
- WOESSNER JF, Jr: Matrix metalloproteinases and their Inhibitors in connective tissue remodelling. FASEB (1991) 5:2145–2154.
- BECKETT RP, DAVIDSON All et al: Recent advances in matrix metalloproteinase inhibitor research. Drug Dis-covery Today (1996) 1:16–26.
- GEARING AJH, BECKETT RP et al: Processing of tumour necrosis factor a precursor by metalloproteinases. Na-ture (1994) 370:555–557.
- MOHLER KM, SLEATH PR et al: Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature (1994) 370:218–220.
- MCGEEHAN GM, BECHERER JD et al: Regulation of tu-mour necrosis factor-a processing by a matrix metallo-proteinase inhibitor. Nature (1994) 370:558–561.
- OGITA T, SATO A et al: Matlystatins, new inhibitors of type IV collagenases fromActtnomatlura atramentaria. J. Antibiotics (1992) 45:1723–1731
References to Patent Literature
- GLAXO, INC., W09400119 (1994).
- MERCK & CO., INC., W09221360 (1992).
- BRITISH BIOTECH LTD., W09005716 (1990).
- CELLTECH LTD., EP-0489577 (1992).
- F. HOFFMAN-LA ROCHE AG, EP-057584 (1993).
- MERCK & GOING., W09412169 (1994).
- SANKYO LTD., W09309097 (1993).
- F. HOFFMAN-LA ROCHE AG, W09533731 (1995).